Moleculin Biotech press release (NASDAQ:MBRX): Q3 GAAP EPS of -$2.85.
As of September 30, 2024, the Company had cash and cash equivalents of $9.4 million and believes that the existing cash and cash equivalents as of September 30, 2024, will be sufficient to fund planned operations into the first quarter of 2025.